Aura Biosciences, Inc. (NASDAQ:AURA) Sees Large Decline in Short Interest

Aura Biosciences, Inc. (NASDAQ:AURA) was the target of a significant drop in short interest in October. As of October 15th, there was short interest totalling 1,050,000 shares, a drop of 8.7% from the September 30th total of 1,150,000 shares. Based on an average daily trading volume, of 184,900 shares, the days-to-cover ratio is currently 5.7 days. Approximately 2.5% of the company’s stock are sold short.

Insider Buying and Selling

In related news, insider Los Pinos Elisabet De sold 24,992 shares of the stock in a transaction on Friday, October 18th. The shares were sold at an average price of $12.04, for a total transaction of $300,903.68. Following the completion of the transaction, the insider now owns 329,847 shares in the company, valued at approximately $3,971,357.88. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In related news, insider Los Pinos Elisabet De sold 24,992 shares of the stock in a transaction that occurred on Friday, October 18th. The stock was sold at an average price of $12.04, for a total transaction of $300,903.68. Following the completion of the transaction, the insider now directly owns 329,847 shares of the company’s stock, valued at approximately $3,971,357.88. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CTO Mark Plavsic sold 7,383 shares of the business’s stock in a transaction that occurred on Wednesday, October 16th. The stock was sold at an average price of $9.85, for a total value of $72,722.55. Following the transaction, the chief technology officer now directly owns 121,132 shares in the company, valued at $1,193,150.20. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 67,259 shares of company stock worth $780,699. 5.40% of the stock is owned by corporate insiders.

Institutional Trading of Aura Biosciences

A number of institutional investors have recently bought and sold shares of AURA. American Century Companies Inc. acquired a new position in shares of Aura Biosciences during the second quarter valued at about $119,000. American International Group Inc. raised its stake in Aura Biosciences by 27.4% during the 1st quarter. American International Group Inc. now owns 17,579 shares of the company’s stock worth $138,000 after buying an additional 3,782 shares during the period. Virtu Financial LLC bought a new position in Aura Biosciences in the first quarter worth approximately $144,000. SG Americas Securities LLC acquired a new stake in Aura Biosciences in the third quarter valued at approximately $169,000. Finally, Rhumbline Advisers grew its stake in Aura Biosciences by 39.6% in the second quarter. Rhumbline Advisers now owns 63,483 shares of the company’s stock valued at $480,000 after acquiring an additional 18,011 shares during the period. Institutional investors own 96.75% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the stock. Scotiabank upped their target price on Aura Biosciences from $20.00 to $23.00 and gave the company a “sector outperform” rating in a research report on Friday, October 18th. Lifesci Capital raised shares of Aura Biosciences to a “strong-buy” rating in a research report on Monday, September 9th. Cowen reissued a “buy” rating on shares of Aura Biosciences in a report on Friday, October 18th. HC Wainwright raised their target price on shares of Aura Biosciences from $21.00 to $22.00 and gave the stock a “buy” rating in a report on Friday, October 18th. Finally, JMP Securities boosted their price target on Aura Biosciences from $19.00 to $23.00 and gave the company a “market outperform” rating in a research note on Friday, September 13th. Five equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $23.00.

Aura Biosciences Stock Down 2.7 %

Shares of NASDAQ AURA traded down $0.28 during trading on Thursday, reaching $10.08. The company had a trading volume of 31,791 shares, compared to its average volume of 175,590. The stock has a market cap of $500.03 million, a P/E ratio of -5.79 and a beta of 0.37. The company’s fifty day moving average price is $9.16 and its 200-day moving average price is $8.27. Aura Biosciences has a 12 month low of $5.99 and a 12 month high of $12.38.

Aura Biosciences (NASDAQ:AURA) last released its earnings results on Thursday, August 8th. The company reported ($0.41) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.04. As a group, equities analysts predict that Aura Biosciences will post -1.7 earnings per share for the current year.

Aura Biosciences Company Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.